Alpelisib (BYL719)
中文名称:阿培利司
目录号:S2814 Purity: 99.96%
Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂,在无细胞试验中IC50为 5 nM,对PI3Kβ/γ/δ具有极弱的作用。Phase 2。
CAS: 1217486-61-7
客户使用Selleck的Alpelisib (BYL719)发表文献214篇
- Nature, 2024 10.1038/s41586-024-08031-6
- Cancer Cell, 2023 41(6):1103-1117.e12
- Cancer Cell, 2023 41(4):660-677.e7
- Signal Transduct Target Ther, 2023 8(1):153
- Cancer Cell, 2021 S1535-6108(21)00284-1
- Cell, 2020 25;181(7):1596-1611.e27.
- Cancer Cell, 2020 S1535-6108(20)30427-X
- Cancer Discov, 2020 10(7):1058-1077
- Nat Med, 2019 25(5):838-849
- Science, 2019 364(6441)
- Nat Genet, 2019 51(2):207-216
- Cancer Discov, 2019 10.1158/2159-8290.CD-18-0830
- Cancer Cell, 2018 34(6):922-938
- Cancer Discov, 2018 8(5):568-581
- Nat Biomed Eng, 2018 2(8):578-588
- Signal Transduct Target Ther, 2017 2:17063
- Cell Discov, 2017 3:16054
- Cancer Discov, 2017 7(9):1018-1029
- Cancer Discov, 2016 6(10):1134-1147
- Nat Cell Biol, 2016 18(12):1324-1335
- Nat Med, 2015 21(9):1038-47
- J Thorac Oncol, 2015 10(12):1736-44
- Blood, 2015 10.1182/blood-2014-11-610329
- Nat Commun, 2024 15(1):7181
- Nat Commun, 2024 15(1):6076
- J Exp Med, 2024 221(3)e20232028
- Cell Rep Med, 2024 S2666-3791(24)00179-4
- Clin Transl Med, 2024 14(5):e1655
- Cancer Lett, 2024 604:217219
- Cell Rep, 2024 43(5):114119
- Cell Rep, 2024 43(12):115061
- Br J Cancer, 2024 10.1038/s41416-023-02555-w
- Cell Rep, 2024 43(10):114784
- Cell Commun Signal, 2024 22(1):428
- NPJ Precis Oncol, 2024 8(1):20
- Mol Oncol, 2024 10.1002/1878-0261.13703
- J Gastroenterol, 2024 10.1007/s00535-024-02192-x
- Front Pharmacol, 2024 15:1443422
- J Cell Mol Med, 2024 28(9):e18374
- Cancers (Basel), 2024 16(20)3520
- J Biol Chem, 2024 300(3):105679
- Mol Carcinog, 2024 10.1002/mc.23743
- Immunol Res, 2024 73(1):20.
- NPJ Syst Biol Appl, 2024 10(1):42
- BMC Vet Res, 2024 20(1):233
- J Turk Ger Gynecol Assoc, 2024 25(3):159-166
- J Exp Clin Cancer Res, 2023 42(1):8
- Oncogene, 2023 10.1038/s41388-023-02676-9 10.3322/caac.21660 10.1001/jama.2021.6021 10.1038/nrdp.2015.65 10.1038/s41575-019-0189-8 10.1038/nature11252 10.1038/s41392
- Front Immunol, 2023 14:1116435
- Clin Sci (Lond), 2023 137(1):1-15
- Mol Cancer Ther, 2023 22(1):63-74
- Cancers (Basel), 2023 15(8)2373
- J Biol Chem, 2023 S0021-9258(23)02125-7
- Front Oncol, 2023 13:1175617
- Clin Exp Med, 2023 10.1007/s10238-023-01227-6
- Life Sci Alliance, 2023 6(11)e202302106
- Oncol Rep, 2023 50(3)166
- Oncol Rep, 2023 49(6)125
- Sci Adv, 2023 9(7):eade8939
- Sci Adv, 2023 9(13):eadd6911
- bioRxiv, 2023 PPR618443
- Res Sq, 2023 rs.3.rs-3154719
- Bioengineering (Basel), 2023 10(2)269
- Nat Commun, 2022 13(1):3181
- Nat Commun, 2022 13(1):2500
- Nat Chem Biol, 2022 10.1038/s41589-022-00996-7
- Cancer Res, 2022 82(12):2269-2280
- Cancer Res, 2022 canres.1397.2021
- Proc Natl Acad Sci U S A, 2022 119(43):e2203180119
- Clin Transl Med, 2022 12(5):e835
- Sci China Life Sci, 2022 10.1007/s11427-021-2140-8
- Oncogene, 2022 41(27):3524-3538
- NPJ Precis Oncol, 2022 6(1):21
- Breast Cancer Res, 2022 24(1):23
- Oncoimmunology, 2022 11(1):2021619
- Mol Oncol, 2022 16(5):1091-1118
- Int J Cancer, 2022 10.1002/ijc.33983
- Cancer Gene Ther, 2022 10.1038/s41417-022-00491-0
- Pharmaceutics, 2022 14(3)590
- Am J Cancer Res, 2022 12(7):3067-3082
- Cancers (Basel), 2022 15(1)135
- Cancers (Basel), 2022 14(10)2397
- Mol Cancer Res, 2022 molcanres.0090.2022-1-28 10:45:29.413
- J Pers Med, 2022 12(2)258
- J Biol Chem, 2022 S0021-9258(22)01309-6
- Oral Oncol, 2022 131:105939
- Front Oncol, 2022 12:862806
- Sci Rep, 2022 12(1):18051
- Molecules, 2022 27(9)2742
- Life Sci Alliance, 2022 5(11)e202201460
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Biomed Res Int, 2022 2022:8568528
- Sci Adv, 2022 8(2):eabh3375
- Cancer Diagn Progn, 2022 2(3):391-404
- Cancer Res Commun, 2022 2(12):1569-1578
- Nat Commun, 2021 12(1):3140
- Cancer Res, 2021 canres.1222.2021
- Cancer Res, 2021 canres.3232.2020
- Cancer Res, 2021 81(17):4603-4617
- Clin Transl Med, 2021 11(11):e589
- Cancer Lett, 2021 S0304-3835(21)00532-2
- Cell Death Dis, 2021 12(8):713
- Cell Death Dis, 2021 12(1):85
- Cell Rep, 2021 34(7):108750
- Cell Chem Biol, 2021 S2451-9456(21)00400-1
- Oncogene, 2021 10.1038/s41388-020-01628-x
- PLoS Pathog, 2021 17(1):e1009216
- Mol Oncol, 2021 10.1002/1878-0261.13046
- Cancer Sci, 2021 112(3):1141-1149
- Mol Cancer Ther, 2021 molcanther.0809.2020
- Oncotarget, 2021 12(7):674-685
- Am J Cancer Res, 2021 11(6):3240-3251
- Mol Cancer Res, 2021 19(6):1026-1039
- Int J Oncol, 2021 10.3892/ijo.2021.5167
- J Biol Chem, 2021 297(2):100942
- Front Oncol, 2021 11:782065
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- J Ovarian Res, 2021 14(1):128
- Cancer Med, 2021 10(7):2370-2379
- Front Med (Lausanne), 2021 8:713312
- STAR Protoc, 2021 2(3):100765
- Nat Commun, 2020 8;11(1):2291
- Genome Med, 2020 18;12(1):17
- Clin Cancer Res, 2020 10.1158/1078-0432.CCR-19-2485
- Clin Cancer Res, 2020 10.1158/1078-0432
- J Exp Clin Cancer Res, 2020 39(1):217
- EMBO Mol Med, 2020 12(4):e11177
- Proc Natl Acad Sci U S A, 2020 117(39):24427-24433
- Cell Death Dis, 2020 11(7):505
- Cell Rep, 2020 31(12):107800
- Cell Rep, 2020 30(5):1400-1416.e6
- Cell Rep, 2020 9;31(10):107753
- Chem Sci, 2020 11(36):9863-9874
- Oncogene, 2020 39(19):3837-3852
- Oncogene, 2020 10.1038/s41388-020-1255-y
- Blood Adv, 2020 4(18):4382-4392
- Cell Oncol (Dordr), 2020 8
- Oncogenesis, 2020 9(10):87
- Cancer, 2020 10.1002/cncr.33071
- Commun Biol, 2020 3(1):546
- Mol Cancer Ther, 2020 5;molcanther.1131.2019
- Cancer Science, 2020 112(3)
- Int J Mol Sci, 2020
- Cancers (Basel), 2020 12(9)E2500
- Mol Cancer Res, 2020 10.1158/1541-7786.MCR-19-0549
- Mol Cancer Res, 2020 25
- J Biol Chem, 2020 14;295(7):1769-1780
- J Biol Chem, 2020 295(8):2336-2347
- Viruses, 2020 12(6):E652
- Sci Rep, 2020 1;10(1):8867
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Oncol Rep, 2020 44(3):863-872
- Cold Spring Harb Mol Case Stud, 2020 12;6(3):a004853
- Small GTPases, 2020 10.1080/21541248
- Mol Syst Biol, 2019 15(3):e8323
- Cancer Lett, 2019 459:145-155
- Cell Rep, 2019 27(1):294-306
- J Dent Res, 2019 98(3):304-312
- Breast Cancer Res, 2019 21(1):20
- Sci Signal, 2019 12(585)
- Brain Pathol, 2019 29(3):336-350
- Cancer Cell Int, 2019 19:348
- Cancer Biol Med, 2019 16(1):66-83
- Cancers (Basel), 2019 11(2)
- Cancers (Basel), 2019 10.3390/cancers11101586
- Front Microbiol, 2019
- Endocrinology, 2019 160(11):2600-2617
- Cancer Res Treat, 2019 51(3):951-962
- Sci Rep, 2019 9(1):9130
- J Immunol, 2019 203(6):1579-1588
- Mol Pharmacol, 2019 95(5):528-536
- Cancer Manag Res, 2019 11:6229-6244
- Pediatr Blood Cancer, 2019 66(8):e27790
- Biochem Biophys Res Commun, 2019 513(3):546-552
- Nat Commun, 2018 9(1):2819
- Nat Commun, 2018 9(1):4550
- J Exp Med, 2018 215(1):159-175
- EMBO J, 2018 37(1):19-38
- Cancer Res, 2018 78(8):2000-2013
- Cancer Res, 2018 78(9):2383-2395
- Cell Death Dis, 2018 9(9):876
- Sci Signal, 2018
- Mol Cancer Ther, 2018 17(10):2091-2099
- Oncotarget, 2018 9(51):29565-29573
- Anal Biochem, 2018 547:66-76
- Nat Commun, 2017 8(1):1090
- Nat Commun, 2017 8(1):1278
- Theranostics, 2017 7(4):974-986
- Sci Data, 2017 4:170139
- Basic Res Cardiol, 2017 112(6):66
- Mol Cancer Ther, 2017 16(4):729-738
- Mol Cancer Ther, 2017 molcanther.0415.2016
- Mol Cancer Ther, 2017 16(3):516-528
- Oncotarget, 2017 8(14):23213-23227
- Oncotarget, 2017 8(47):81794-81802
- Int J Oncol, 2017 50(6):2049-2058
- Mol Cancer Res, 2017
- PLoS One, 2017 12(2):e0171221
- Nat Commun, 2016 7:11971
- Cell Rep, 2016
- Oncogene, 2016 10.1038/onc.2016.216
- Elife, 2016 10.7554/eLife.18489
- Elife, 2016
- Oncotarget, 2016
- Proc Natl Acad Sci USA, 2015
- Proc Natl Acad Sci U S A, 2015 112(45):13976-81
- Oncotarget, 2015 6(19):17501-13
- Cell Signal, 2015 27(12):2389-400
- Endocrinology, 2015 156(1):218-30
- Anticancer Res, 2015 35(1):175-82
- Br J Haematol, 2014 165(1):89-101
- Anal Bioanal Chem, 2014 406(15):3743-54
化学信息&溶解度
分子量 | 441.47 |
分子式 | C19H22F3N5O2S |
CAS号 | 1217486-61-7 |
Smiles | CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 88 mg/mL ( 199.33 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 88 mg/mL ( 199.33 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 2 mg/mL Water : Insoluble DMSO : 88 mg/mL ( 199.33 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 2 mg/mL Water : Insoluble DMSO : 88 mg/mL ( 199.33 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 88 mg/mL ( 199.33 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 59 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:4.4mg/ml
(9.97mM)
操作示例:以 1 mL 工作液为例,取50μL88mg/ml的澄清DMSO储备液加到 400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。